SCHEMBL30765744

SCHEMBL30765744

CCCCOC(=O)Cn1c(O[C@@H]2CO[C@H]3[C@@H]2OC[C@H]3OC)ncc(NCCCc2ccccc2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 6/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
GAA P10253 1/20 0.37
ALDH1A1 P00352 3/20 0.36
TSHR P16473 3/20 0.36
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ASPH Q12797 1/20 0.35
RIOX2 Q8IUF8 1/20 0.35
KDM8 Q8N371 1/20 0.35
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765503 0.89 BCHE (0.41) BCHELMNAKDM4EASPHRIOX2
SCHEMBL30765950 0.88 BCHE (0.38) BCHEALDH1A1KDM4EASPHRIOX2
SCHEMBL31558528 0.88 BCHE (0.40) BCHEKDM4EASPHRIOX2KDM8
SCHEMBL30765608 0.83 GAA (0.41) BCHEMEN1KMT2AL3MBTL1GAA
SCHEMBL30765638 0.82 GAA (0.41) BCHEL3MBTL1GAA
SCHEMBL30765946 0.79 F2 (0.39) BCHE
SCHEMBL30765978 0.79 ELANE (0.41) BCHELMNAKDM4EASPHRIOX2
SCHEMBL30765476 0.78 ELANE (0.40) BCHEALDH1A1KDM4ENPC1RAB9A
SCHEMBL30765606 0.77 MEN1 (0.44) MEN1KMT2AL3MBTL1GAAALDH1A1
SCHEMBL30765714 0.77 MEN1 (0.43) MEN1KMT2AL3MBTL1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed